Abstract
The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.
| Original language | English |
|---|---|
| Pages (from-to) | 2539-2547 |
| Number of pages | 9 |
| Journal | Journal of Neurology |
| Volume | 262 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 1 2015 |
Fingerprint
Keywords
- 3-D gait analysis
- De novo Parkinson
- Kinematics
- Non-stationary locomotion
- Rotigotine
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. / Serrao, Mariano; Ranavolo, Alberto; Conte, Carmela; Davassi, Chiara; Mari, Silvia; Fasano, Alfonso; Chini, Giorgia; Coppola, Gianluca; Draicchio, Francesco; Pierelli, Francesco.
In: Journal of Neurology, Vol. 262, No. 11, 01.11.2015, p. 2539-2547.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study
AU - Serrao, Mariano
AU - Ranavolo, Alberto
AU - Conte, Carmela
AU - Davassi, Chiara
AU - Mari, Silvia
AU - Fasano, Alfonso
AU - Chini, Giorgia
AU - Coppola, Gianluca
AU - Draicchio, Francesco
AU - Pierelli, Francesco
PY - 2015/11/1
Y1 - 2015/11/1
N2 - The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.
AB - The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.
KW - 3-D gait analysis
KW - De novo Parkinson
KW - Kinematics
KW - Non-stationary locomotion
KW - Rotigotine
UR - http://www.scopus.com/inward/record.url?scp=84956840771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956840771&partnerID=8YFLogxK
U2 - 10.1007/s00415-015-7883-4
DO - 10.1007/s00415-015-7883-4
M3 - Article
C2 - 26303834
AN - SCOPUS:84956840771
VL - 262
SP - 2539
EP - 2547
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
IS - 11
ER -